Future Cardiol

• 

  Publication Venue For

  • Vorapaxar in the treatment of cardiovascular diseases..  16:373-384. 2020
  • Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy..  16:69-75. 2020
  • The need for sex-specific precision biomarkers for antiplatelet therapies..  13:419-422. 2017
  • Drug delivery and therapeutic impact of extended-release acetylsalicylic acid..  12:45-58. 2016
  • Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial..  11:585-595. 2015
  • Current and emerging modalities for detection of cardiotoxicity in cardio-oncology..  11:471-484. 2015
  • Emerging role of contrast-enhanced MRI in diagnosing vascular malformations..  10:479-486. 2014
  • Platelet RNA as a novel biomarker for the response to antiplatelet therapy..  10:9-12. 2014
  • PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection..  9:785-797. 2013
  • Elinogrel: pharmacological principles, preclinical and early phase clinical testing..  6:445-453. 2010
  • REPAIR-AMI: stem cells for acute myocardial infarction..  3:137-140. 2007
  • Clinical implications of vulnerable plaque..  2:721-731. 2006
  • New therapeutic possibilities for vein graft disease in the post-edifoligide era..  2:493-501. 2006
  • Antiplatelet therapy: current strategies and future trends..  2:343-366. 2006
  • The African-American heart failure trial: a new look at old drugs..  1:311-313. 2005
  • Progenitor cell therapy of ischemic heart disease: the new frontier..  1:87-98. 2005